Kornimate/medical-research-clean huggingface dataset:
circulating biomarkers to identify thyroid cancer

Conditions: Thyroid Cancer; Thyroid Cancer, Papillary; Benign Thyroid Tumor

Summary: this study aimed to identify the potential circulating biomarkers of protein, mrnas, and long non-coding rnas (lncrnas) to diﬀerentiate the papillary thyroid cancers from benign thyroid tumors. methods: the study population of 100 patients was classified into identification (10 patients with papillary thyroid cancers and 10 patients with benign thyroid tumors) and validation groups (45 patients with papillary thyroid cancers and 35 patients with benign thyroid tumors). the sengenics immunome protein array combined data mining approach using the open targets platform was used to identify the putative protein biomarkers, and their expression validated using the enzyme-linked immunosorbent assay. next-generation sequencing by illumina hiseq was used for the detection of dysregulated mrnas and lncrnas. the website timer v2.0 helped identify the putative mrna biomarkers, which were significantly over-expressed in papillary thyroid cancers than in adjacent normal thyroid tissue. the mrna and lncrnas biomarker expression was validated by a real-time polymerase chain reaction.

novel biomarkers identification from liquid biopsy samples is in great demand for the diagnosis for malignant diseases. generally, blood sampling is less invasive and could be carried out repeatedly. in addition to protein markers, circulating nucleic acids are promising sources of cancer biomarkers , since circulating nucleic acids provide information on the genome or gene expression , and harbor wealth of health and disease status information. the long non-coding rnas (lncrnas) are the transcripts longer than 200 nucleotides in length and act as prominent regulators of gene expression. accumulating evidence demonstrated the involvement of lncrna dysregulation in a variety of cancers, and their expression is associated with cancer development and metastasis. this study was designed to identify the potential protein and rna biomarkers in the blood for diﬀerentiating a malignant thyroid tumor from a benign thyroid nodule. in this study, only patients with papillary thyroid carcinoma, the most common type of thyroid cancer, were chosen for comparison with those with benign thyroid tumors to simplify the comparison.

Eligibility criteria:
inclusion criteria: * patients with thyroid nodules who received total or subtotal thyroidectomy * patients aged 20 years and above exclusion criteria: * patients with any other type of cancer, immunocompromised disease, or autoimmune disease.
cytogenetic analysis of bone marrow specimen prior to high dose chemotherapy and autologous stem cell transplantation in patients with non-hodgkin's lymphoma or hodgkin's disease

Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease

Summary: cytogenetic analysis of bone marrow specimen prior to high dose chemotherapy and autologous stem cell transplantation in patients with non-hodgkin's lymphoma or hodgkin's disease


Eligibility criteria:
inclusion criteria: * patients with non-hodgkin's lymphoma or hodgkin's disease

Keywords: cytogenetic analysis of bone marrow specimen in non-hodgkin's lymphoma or hodgkin's disease
a telemedicine solution for remote support of rehabilitation, for patients undergoing, total hip arthroplasty surgery

Conditions: Quality of Life; Anxiety

Summary: the rrs project is a randomized clinical trial documenting the effect of remote rehabilitation and support via a telemedicine solution for patients undergoing an optimized fast-track orthopedic surgery procedure with the implementation of a total hip arthroplasty. with the telemedicine solution the investigators will support and try to motivate the patient to be discharged after only one day of hospitalization.

this phd study evaluates the effect of an information technology solution containing rrs. the way it supports, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital. the parameters evaluated will be: length of stay, health-related quality-of-life (hrqol), functional outcome, pain, anxiety, complications and an evaluation of the socio-economic effect. the aim of the study generates the following hypotheses and focus for publication * length of stay is lower for the intervention group compared to the control group. * the average quality of life measured with eq-5d will either be the same or higher when comparing the intervention group with the control group. * compared to the control group the functional outcome of the intervention group measured with oxford hip score (ohs) and timed up and go (tug) will be the same or better. * complications measured as luxations, infections, and reoperations are the same or lower in the intervention group compared to the control group. * there will be a correlation between patients with the highest level of psychological problems and symptoms of psychopathology measured with symptom checklist-90-r, and the postoperative outcome measured with eq5d, anxiety and tug. * there will be a correlation between support persons with the highest level of psychological problems and symptoms of psychopathology measured with symptom checklist-90-r, and the postoperative outcome measured with eq5d, anxiety and tug for the patient they are related to. * the socio-economic costs will be lower for the intervention group compared to the control group based on self reported data and data collected from official databases. this study will be conducted as a piggy back to the rct.

Eligibility criteria:
inclusion criteria: * patients qualified to go trough at joint-care procedure after the guidelines from regionshospitalet silkeborg. exclusion criteria: * previous hip surgery with the implantation of a total hip arthroplasty. * patients living more than approximately 60 kilometers from the regionshospitalet silkeborg. * patients with no 3g tele-net at their home address. * patients with the need of danish interpretation.

Keywords: length of stay timed up and go
in vivo treg expansion and graft-versus-host disease prophylaxis

Conditions: Graft-Versus-Host-Disease

Summary: il-2 add-back post allogeneic hematopoietic stem cell transplant (hsct), combined with sirolimus (sir), tacrolimus (tac) will optimize treg reconstitution and prevent graft versus host disease (gvhd).

1) determine if a gvhd prophylaxis regimen of il-2/sir/tac enhances in vivo treg differentiation and growth; 2) study the safety and effects of il-2/sir/tac on the incidence of acute and chronic gvhd; 3) evaluate the influence of dual il-2 supplementation and mammalian target of rapamycin (mtor) inhibition on t cell-specific signaling pathways and the polarization of emerging t helper cells.

Eligibility criteria:
inclusion criteria: * patients must have an available 8/8 human leukocyte antigen (hla)-a, -b, -c, and -drb1 matched-related or unrelated donor allogeneic hematopoietic peripheral blood stem cell graft. * acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid leukemia, or myeloproliferative neoplasms requiring a matched allogeneic hsct. * acute leukemia (aml or all) must be in complete remission defined as: \ 20% cellular, and peripheral absolute neutrophil count \>1000/µl (platelet recovery is not required). * myelodysplasia (mds) and chronic myeloid leukemia (cml): must have \<5% marrow blasts. * myeloproliferative neoplasms (mpn): must have \<5% peripheral / marrow blasts. * adequate vital organ function: 1. left ventricular ejection fraction (lvef) ≥ 45% by multi gated acquisition (muga) scan or echo 2. forced expiratory volume at one second (fev1), forced vital capacity (fvc), and adjusted diffusing lung capacity oxygenation (dlco) ≥ 50% of predicted values on pulmonary function tests 3. transaminases (ast, alt) \< 2 times upper limit of normal values 4. creatinine clearance ≥ 50 cc/min. * performance status: karnofsky performance status score ≥ 80% * donor eligibility: eligible donors will include healthy sibling, relative or unrelated donors that are matched with the patient at hla-a, b, c, and drb1 by high resolution typing. exclusion criteria: * active infection not controlled with appropriate antimicrobial therapy * history of hiv, hepatitis b, or hepatitis c infection * anti-thymocyte globulin, alemtuzumab, bortezomib, or cyclophosphamide administered within 14 days before or planned to receive with hct conditioning or as part of gvhd prophylaxis in the 14 days after hct. * hypersensitivity to recombinant human il-2 * chronic lymphocytic leukemia, hodgkin lymphoma, and non-hodgkin lymphoma are excluded as these malignancies may express the il-2 receptor and pose a potential growth signal to any present disease. * sorror's co-morbidity factors with total score \>4

Keywords: gvhd allogeneic hematopoietic cell transplant
methotrexate - inadequate response device sub-study

Conditions: Rheumatoid Arthritis (RA)

Summary: the purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.


Eligibility criteria:
inclusion criteria: * men and women, ages ≥ 18 * participants who are considered methotrexate inadequate responders (mtx-ir) * 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint count) * participants were to have been enrolled in the main mtx-ir study and been treated with open label abatacept for at least 3 months in the long term period exclusion criteria: * participants who failed one or multiple anti-tumor necrosis factor (tnf) therapies * participants who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematosus) * participants with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules) * participants with severe chronic or recurrent bacterial infections * participants who have received treatment with rituximab
nab-paclitaxel combined with s-1 treating diffuse type of stage ⅲ gastric cancer

Conditions: Gastric Cancer

Summary: investigators assessed the effectiveness of nab-paclitaxel combined with s-1 treating diffuse type of stage ⅲ gastric cancer as adjuvant setting

adjuvant chemotherapy is still the standard of care for stage ⅲ gastric cancer. till now, oxaliplatin with capecitabine or s1 still the standard chemotherapy regimen. howerver, the prognosis of diffuse type gastric cancer patients is still poor even after adjuvant chemotherapy of xelox or s1 regimen. several retrospective, single institutional studies have shown that the addition of nab-paclitaxel to s1 can prolong the survival of advanced gastric cancer with diffuse type.however, the effection of nab-paclitaxel and s1 is unknown in diffuse gastric cancer patients after radical surgery. we assessed the effectiveness of radical surgery following docetaxel, nab-pacitaxel and s1 therapy for gastric cancer with diffuse type.

Eligibility criteria:
inclusion criteria: * gastric cancer patients after radical resection * diffuse type gastric cancer stage iii exclusion criteria: * patients who have metastasis disease * patients who can not tolerate chemotherapy
micro-ultrasound for the detection and localization of prostate cancer tumors in patients undergoing radical prostatectomy

Conditions: Prostate Carcinoma

Summary: this trial studies the ability of micro-ultrasound to detect and characterize prostate cancer tumors in patients undergoing radical prostatectomy (removal of the entire prostate and some of the tissue around it). usually multiparametric magnetic resonance imaging is used for the detection and targeted therapy of prostate cancer, but its accuracy remains imperfect. micro-ultrasound may be superior as it provides real-time tumor visualization which may simplify and improve prostate cancer targeted therapy. this may also reduce the need for and substantial costs of radical prostatectomy.

primary objective: i. determine if micro-ultrasound (us) can be used to identify prostate cancer foci with equivalent (non-inferior) performance relative to multiparametric magnetic resonance imaging (mpmri). secondary objective: i. determine if micro-us can be used to contour prostate cancer foci with equivalent (non-inferior) accuracy to mpmri. tertiary objective: i. determine if ex vivo micro-us images have quality comparable to in vivo micro-us images. quaternary objective: i. determine if micro-us can be used to evaluate suspicion of extracapsular extension (ece) with equivalent (non-inferior) accuracy to mpmri. outline: patients may undergo transrectal micro-ultrasound scan (trus) prior to standard-of-care radical prostatectomy. following radical prostatectomy, removed glands are scanned and micro-us, standard of care mpmri, and whole mount images are analyzed and compared.

Eligibility criteria:
inclusion criteria: * standard-of-care mpmri within the past 12 months * biopsy-proven prostate cancer, gleason grade \>= 3+3 * maximum posterior-to-anterior prostate dimension of =\< 6 cm * scheduled to receive standard-of-care radical prostatectomy exclusion criteria: * maximum posterior-to-anterior prostate dimension greater than 6 cm * prior radiation or focal treatment for prostate cancer * inability to have a transrectal ultrasound scan * prostate biopsy \< 4 weeks prior to surgery
protective effects of delayed cord clamping in very low birth weight (vlbw) infants

Conditions: Intraventricular Hemorrhage; Sepsis

Summary: the purpose of this study is to determine whether the intervention of delaying cord clamping for 30 to 45 seconds followed by one milking of the cord while simultaneously lowering the vlbw infants below the introitus will result in less bleeding in the brain and fewer infections while in the neonatal intensive care unit (nicu) and better motor skills at 7 months corrected age. the investigators will attempt to identify the mechanisms of effect through measurement of biologic markers.

the current obstetrical practice at birth in the united states is that the umbilical cord of the very low birth weight (vlbw) infant is clamped immediately. when immediate cord clamping occurs, up to 25% of the fetal-placental blood volume may be left in the placenta acutely increasing vulnerability to hypovolemia. hypovolemia can precipitate a cascade of physiologic events including poor tissue perfusion, ischemia, and initiation of the fetal/neonatal inflammatory response. intraventricular hemorrhage (ivh) is a major cause of brain injury for preterm infants and is a predictor of poor neurodevelopment outcomes. late onset sepsis (los) is also associated with morbidity and mortality in the nicu and later developmental delay. of the approximately 57,000 infants born annually at less than 1500 grams, 10% develop cerebral palsy and 25 to 50% show later cognitive and behavioral deficits affecting school performance with higher rates found in males. we propose a trial with a sample of 212 randomized infants to validate our prior findings that delaying the cord clamping lowers the incidence of intraventricular hemorrhage and late onset sepsis, and to identify the mechanisms of effect through the study of biologic markers including measurement of cytokines, circulating stem cells, and red cell volume. enrolled women in preterm labor will be randomized at birth to the immediate cord clamping group or the delayed clamping group. assessment of motor outcomes is planned at 7 months corrected age. this study will help to establish a scientific basis for the timing of cord clamping of vlbw infants. the innovation of this study is in the simplicity of delaying cord clamping for 30 to 45 seconds and lowering the vlbw infants at birth. this low-tech change in a clinical practice has the potential to reduce the risk of disease and disability and to improve the neonatal and early childhood outcomes for these most vulnerable preterm infants.

Eligibility criteria:
inclusion criteria: * pregnant women between 24 and 31.6 weeks gestation at risk of delivery * vaginal or cesarean birth exclusion criteria: * congenital anomaly * multiple gestation * intent to withhold or withdraw care * severe or multiple maternal illnesses * mothers who are institutionalized or psychotic

Keywords: intraventricular hemorrhage sepsis motor function motor functioning at 7 months corrected age cytokines in cord blood and at 6 and 20 hours of age stem cells in cord blood and at 20 hours of age
dna repair enzyme signature in head and neck cancer (chemrad)

Conditions: Head Cancer; Neck Cancer

Summary: squamous cell carcinoma (hnscc) is the most frequent form of head and neck cancer. the therapeutic choice depends on the stage of the disease and the habits of the medical teams. surgery, radiotherapy and chemotherapy can be used, alone or combined. however, none of the existing strategies has proven its superiority. chemotherapy and radiotherapy induce dna damages in the tumor cells. however, cells have the ability to induce dna reparation, capable of causing treatment resistance. dna reparation in non-tumor tissues can also explain the toxicity of cancer treatments. investigation of dna repair pathways involved in chemo- or radiation resistance could offer a good strategy for identifying biomarkers or indicators of treatment response. this study will explore the capacity of a comprehensive functional approach that addresses several pathways, based on the use of three innovative patented technologies, to classify the tumor response of hnscc patients to treatments according to their dna repair enzyme signature. our hypothesis is that taking into account various clinical parameters (e.g. patient and tumor characteristics), treatment strategy and measuring the dna repair enzyme signature would create patients' profiles and optimize their management.


Eligibility criteria:
inclusion criteria: * age over 18 years old; * hnscc proven on a biopsy, located in the oral cavity or the oropharynx (the tumor must be accessible to a biopsy during an outpatient visit); * tumor accessible to a biopsy under local anesthesia; * tnm classification: any stage except m1; * eligible for radiotherapy as a curative treatment; * no surgery planned as exclusive treatment; * able to comply with the scheduled visits; * affiliated to or beneficiary of a social security system (or equivalent) ; * having given written informed consent prior to any procedure related to the study. exclusion criteria: * recurrence or second cancer in a previously irradiated area; * nasopharyngeal carcinoma; * tumor requiring general anesthesia to perform the biopsy; * radiotherapy planned to be provided outside of the investigation center; * pregnant or lactating woman; * adult ward of court (under guardianship or trusteeship).

Keywords: dna repair enzyme signature instrinsic radio- or chemo-resistance treatment-induced radio- or chemo-resistance
comparison of mco hd on markers of vascular health compared with on-line haemodiafiltration

Conditions: End Stage Renal Disease; Cardiovascular Diseases; Inflammation

Summary: the aim of this study is to evaluate haemodialysis treatment using a medium cut-off dialysis membrane (theranova) compared with on-line haemodiafiltration treatment with respect to markers of endothelial health (plasma endothelial microvesicle levels, pro-inflammatory and pro-coagulant markers). this study will also compare the 2 treatment modalities with respect to several other outcome measures including patient-reported outcome measures, haemodynamic parameters and advanced glycation end-products.

to date, methods of improving outcomes for haemodialysis patients have focused on improving small molecule clearance (urea); however, the benefits do not appear to be linear and increasing kt/v above 1.3 shows no benefit. current dialysis therapies are unable to provide effective clearance of larger "middle molecules" (between 20kda and 60kda) and retention of these molecules may be linked to poor outcomes in haemodialysis patients. medium cut-off (mco) dialysis membranes have been recently developed to address this area of unmet need and provide an enhanced clearance of some larger middle molecules when compared with high flux haemodialysis (hfhd) and even high volume haemodiafiltration (hdf). the clinical benefit of this therapy is yet to be defined. the aim of this study is to investigate the effect of hdx therapy (expanded haemodialysis therapy through the use of a mco haemodialysis membrane- theranova) on vascular endothelial and inflammatory biomarkers compared with high volume hdf therapy. through the use of endothelial microvesicles (emv) as a marker of vascular endothelial health, which strongly correlate with cardiovascular outcomes in end-stage real disease (esrd) patients, this pilot study will take the first steps into exploring whether hdx treatment provides clinical benefits in addition to its simplicity of implementation. additionally, other important parameters, such as dialysis recovery time, patient-reported outcome measures and volume management will also be explored and compared with high volume hdf.

Eligibility criteria:
inclusion criteria: * established on in-centre haemodiafiltration (hdf) for greater than 12 weeks with a minimum of 3 treatment sessions per week * ability to consent exclusion criteria: * planned live donor renal transplant within 6 months (with confirmed date) * planned switch in renal replacement modality (ie. to peritoneal dialysis or home haemodialysis) * clinician predicted prognosis \< 6 months

Keywords: hemodialysis haemodialysis hemodiafiltration haemodiafiltration dialysis membrane endothelial microvesicles pulse wave velocity